Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 26S subgenomic promoter (26S SGP) is a highly conserved RNA sequence element found in the genomes of viruses within the Alphavirus genus, such as Chikungunya virus and Sindbis virus (Strauss & Strauss, 1994, Microbiol Rev). It serves as the internal initiation site for the viral RNA-dependent RNA polymerase (replicase) to transcribe a subgenomic mRNA from the full-length negative-strand RNA intermediate (Jose et al., 2009, Future Microbiol). This subgenomic RNA is essential because it encodes the viral structural proteins, including the capsid and envelope glycoproteins, which are required for the assembly and budding of new progeny virions (Frolov et al., 1996, PNAS). Because the production of these structural components is entirely dependent on the 26S SGP, it represents a critical regulatory node in the viral life cycle and an attractive target for antiviral strategies. Experimental approaches to inhibit this target include the use of antisense oligonucleotides (ASOs) and RNA interference (RNAi) to disrupt the interaction between the promoter and the viral replicase complex (Geiss et al., 2005, J Virol). Beyond its role in infection, the 26S subgenomic promoter is a cornerstone of biotechnology, frequently utilized in alphavirus-based expression vectors to drive high-level production of recombinant proteins or vaccine antigens in mammalian cells (Lundstrom, 2014, Viruses). The promoter's efficiency and specificity make it a powerful tool for transient gene expression and the development of next-generation mRNA vaccines. However, therapeutic targeting of this sequence faces challenges such as the potential for viral escape through point mutations and the need for effective delivery of nucleic acid-based inhibitors to infected tissues.
Inhibition of subgenomic RNA synthesis by blocking viral replicase binding or elongation
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 26S subgenomic promoter (26S SGP) (26S SGP).